Yasunari K, Kohno M, Kano H, Minami M, Yoshikawa J
First Department of Internal Medicine, Osaka City University Medical School, Osaka, Japan.
Circulation. 2000 May 16;101(19):2302-8. doi: 10.1161/01.cir.101.19.2302.
To elucidate the roles of vascular D(1)-like receptors in atherosclerosis, the effects of the specific D(1)-like agonists on platelet-derived growth factor (PDGF)-BB-mediated oxidative stress in vascular smooth muscle cells (VSMCs) were studied.
Immunohistochemical studies demonstrated the coexistence of D(1A) and D(1B) dopamine receptors in VSMCs. Western blotting revealed a band of approximately 70 kDa for D(1A) and D(1B) dopamine receptors. VSMCs stimulated by PDGF-BB exhibited increased oxidative stress directly measured by flow cytometry. These effects were prevented by dopamine, SKF 38393, or YM 435, and this prevention was reversed by Sch 23390. These effects were blocked by a specific protein kinase A (PKA) inhibitor, N-(2-[p-bromocinnamylamino]ethyl)-5-isoquinolinesulfonamide (H 89). The PDGF-BB-mediated increase in oxidative stress of VSMCs was significantly suppressed by the indirect phospholipase D (PLD) inhibitor suramin or the specific protein kinase C (PKC) inhibitor calphostin C. Both antisense but neither sense nor scrambled oligonucleotides to D(1A) and D(1B) receptors inhibited dopamine-induced suppression of increase in oxidative stress of VSMCs induced by PDGF-BB.
These findings suggest that vascular D(1)-like receptors (D(1A) and D(1B) receptors) inhibit any increase in oxidative stress of VSMCs, possibly through activation of PKA and suppression of PLD and PKC.
为阐明血管D1样受体在动脉粥样硬化中的作用,研究了特异性D1样激动剂对血小板衍生生长因子(PDGF)-BB介导的血管平滑肌细胞(VSMC)氧化应激的影响。
免疫组织化学研究表明VSMC中存在D1A和D1B多巴胺受体。蛋白质印迹法显示D1A和D1B多巴胺受体有一条约70 kDa的条带。经PDGF-BB刺激的VSMC通过流式细胞术直接检测显示氧化应激增加。多巴胺、SKF 38393或YM 435可预防这些效应,而Sch 23390可逆转这种预防作用。这些效应被特异性蛋白激酶A(PKA)抑制剂N-(2-[对溴肉桂酰胺基]乙基)-5-异喹啉磺酰胺(H 89)阻断。间接磷脂酶D(PLD)抑制剂苏拉明或特异性蛋白激酶C(PKC)抑制剂钙泊三醇C可显著抑制PDGF-BB介导的VSMC氧化应激增加。针对D1A和D1B受体的反义寡核苷酸而非正义或随机寡核苷酸均抑制多巴胺诱导的对PDGF-BB诱导的VSMC氧化应激增加的抑制作用。
这些发现表明血管D1样受体(D1A和D1B受体)可能通过激活PKA以及抑制PLD和PKC来抑制VSMC氧化应激的任何增加。